SmithKline Beckman Corp. posted second-quarter earnings of...

SmithKline Beckman Corp. posted second-quarter earnings of $98.7 million, down 25% from the same 1987 quarter. A major reason for the sharp decline was lower-than-expected sales of the Philadelphia-based pharmaceutical company’s two major drugs, Tagamet and Dyazide, SmithKline said.